NovaBridge Biosciences (NBP) Equity Average (2018 - 2025)
NovaBridge Biosciences (NBP) has 7 years of Equity Average data on record, last reported at $244.9 million in Q4 2025.
- On a quarterly basis, Equity Average rose 16.9% to $244.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $244.9 million, a 16.9% increase, with the full-year FY2025 number at $216.1 million, down 2.62% from a year prior.
- Equity Average reached $244.9 million in Q4 2025 per NBP's latest filing, up from $227.8 million in the prior quarter.
- Over the last five years, Equity Average for NBP hit a ceiling of $847.3 million in Q2 2021 and a floor of $197.5 million in Q2 2025.
- A 5-year average of $406.1 million and a median of $244.9 million in 2025 define the central range for Equity Average.
- Peak YoY movement for Equity Average: plummeted 43.13% in 2023, then increased 16.9% in 2025.
- Tracing NBP's Equity Average over 5 years: stood at $779.4 million in 2021, then tumbled by 35.29% to $504.4 million in 2022, then decreased by 25.99% to $373.3 million in 2023, then tumbled by 43.87% to $209.5 million in 2024, then grew by 16.9% to $244.9 million in 2025.
- Business Quant data shows Equity Average for NBP at $244.9 million in Q4 2025, $227.8 million in Q3 2025, and $197.5 million in Q2 2025.